Daewoong Pharmaceuticals said Tuesday that it has published the results of RESTORE, its multinational clinical trial for Erdos, an expectorants treatment.
It conducted the RESTORE study in 467 patients with stable or moderate chronic obstructive pulmonary disease (COPD) at 47 institutions in 10 European countries for a year. It was to evaluate the efficacy and safety of the Erdos’s minimum approved dose of 600 mg in COPD patients when combined with conventional therapy.
As a result, groups treated with Erdos showed a significant decrease in the deterioration rate. Compared with the placebo group, the Erdos-treated group’s overall COPD exacerbation rate and exacerbation duration also fell 19.4 percent and 24.6 percent, respectively. Its mild exacerbation rate, too, dropped 57.1 percent.
“The results from the clinical study have provided the basis for recommending Erdos as a long-term treatment for COPD treatment guidelines,” said Park Young-hun 박영훈, product manager at Daewoong 대웅제약. “Erdos can reduce overall deterioration in COPD patients and can be used for symptoms such as symptomatic coughs, sputum, and shortness of breath.”
The results of the clinical study were published in the latest issue of the European Respiratory Journal.
<© Korea Biomedical Review, All rights reserved.>